Skip to main content
Equibles
MREO logo

MREO · Mereo BioPharma Group plc

Track MREO — free

Use MREO with AI

Ask our own analyst here, or connect this data to the AI you already use.

Ask ALVIS about MREO

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$0.25 -0.02 (-7.17%) At close · Aug 28
Rebalance outlook locked
Market Cap
$43.44M
Shares
159.69M

Price & Indicators

Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$0.25 Open$0.27 Day$0.25–0.27 52W close$0.24–2.31 Avg vol 30d6.8M Short int4.3M · 2.7% float · 1.0d Short vol52% Last earningsAug 11, 2026 DataJan 2020–Aug 2026 Filing10-Q · Aug 11

Up next

FQ3-26 quarter ends
~Sep 30, 2026 Est
Latest filing: 10-Q
filed Aug 11, 2026

Equibles Rating

blended score · not investment advice
Overall
Strong Sell
SellHoldBuy
Technical Sell Momentum Very Weak Sentiment Bearish Fundamentals Fair Quant / Vol Very High
Market backdrop VIX 14.4 · calm Equity put/call 0.39
Technical
price trend
Sell
50 / 200-day cross No cross
Price vs 200-day avg −59%
below
Price vs 50-day avg −18%
below
RSI (14) 33
neutral
MACD trend Negative
52-week position 1%
near low
Volume (OBV) Bullish div.
accumulating
Momentum
relative strength
Very Weak
1-month return −26%
trailing
6-month return −36%
trailing
YTD return −39%
this year
Relative strength −49%
vs S&P · 6-mo
Sentiment
smart money
Bearish
Trend (MA cross) No cross
50d $0 › 200d $1 — 200d above 50d
Institutional flow Distributing
-5% holders QoQ · +14 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
2.70% of float · ▲ +26.5% MoM · 1.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
61 holders — mid 3-yr range
Squeeze score 46
elevated · 0–100
Fundamentals
Fair
EPS growth +17%
Y/Y
Free cash flow $-31.0M
Quant / Vol
risk profile
Very High
Volatility 129%
annualized · 1-yr
Max drawdown −90%
past year
ATR 9.4%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Sell
4 · 2 · 1
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−59% Bearish
Price vs 50-day avg
−18% Bearish
RSI (14)
33 Neutral
MACD trend
Negative Bearish
52-week position
1% Bearish
Volume (OBV)
Bullish div. Bullish
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross) No cross
50d $0 › 200d $1 — 200d above 50d
Institutional flow Distributing
-5% holders QoQ · +14 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
2.70% of float · ▲ +26.5% MoM · 1.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
61 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $0 Now $0 · 1% Range high $2
vs 200-day avg -59% vs 50-day avg -18%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings
Metric Latest Period YoY
Total ADS equivalents 159,618,608 June 30, 2026 —
Total ordinary shares issued 798,093,044 June 30, 2026 —

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
MREO
Mereo BioPharma Group plc
this stock
$43.44M -39.4% — — 2.7%
VRTX
Vertex Pharmaceuticals Inc / Ma
 $137.30B +19.5% +46.2% 31.6 1.6%
REGN
Regeneron Pharmaceuticals, Inc.
 $81.27B +2.9% +20.8% 19.6 2.3%
ARGX
Argenx SE
 $65.12B +21.7% — — 1.9%
CSLLY
Csl Ltd
 $59.92B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Reducing
Holders
61
% held
35.9%
Net QoQ
-18.9M sh
Top holder
Rubric Capital Management…
Held Float
View
Held by Funds
Fund positions
6
View
Short & Settlement
Short Interest Rising
Shares short
4.3M
Days to cover
1.0d
Change
+902.9K sh
View
Short Volume
Short vol %
52%
As of
Aug 28, 2026
Short Total
View
Fails to Deliver
FTD shares
50
Value
$15
As of
Jul 24, 2026
View
Off-Exchange
Off-exchange %
74.2%
Week of
Jul 20, 2026
Off-exch Lit
View
Financials
Financials
Revenue (FY)
$500.0K
Net income (FY)
$-41.9M
EPS diluted
$-0.05
View
Filings
SEC Filings
Latest
8-K
Filed
Aug 19, 2026
This year
15
View
Proposed Sales
Value
$131.8K
Shares
28.3K
Filed
Sep 12, 2024
View
Exempt Offerings
Offering
$70.0M
Filed
Jun 12, 2020
View
Earnings & Events
Earnings Calls
Last call
Aug 11, 2026
View

Performance

5D 20D 120D MTD YTD
MREO -13.1% -26.3% -35.6% -26.3% -39.5%
SPY +0.5% +3.0% +13.4% +3.0% +12.8%
vs SPY -13.5% -29.3% -49.0% -29.3% -52.3%
Key facts CIK 1719714 CUSIP 589492107 13F (30d) 56 filings 55 filers Visit website Investor relations

Report a Problem

Category
Description
Email (optional, for follow-up)